Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.56 SEK | +2.88% | +8.39% | +58.85% |
05-21 | Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting | CI |
04-18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Sales 2024 * | 239M 22.6M 30.86M | Sales 2025 * | 343M 32.37M 44.21M | Capitalization | 2.66B 251M 343M |
---|---|---|---|---|---|
Net income 2024 * | -735M -69.43M -94.83M | Net income 2025 * | -712M -67.26M -91.86M | EV / Sales 2024 * | 13.1 x |
Net Debt 2024 * | 474M 44.78M 61.16M | Net Debt 2025 * | 733M 69.28M 94.62M | EV / Sales 2025 * | 9.9 x |
P/E ratio 2024 * |
-3.65
x | P/E ratio 2025 * |
-4.33
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | +2.88% | ||
1 week | +8.39% | ||
Current month | +48.60% | ||
1 month | +58.09% | ||
3 months | +30.71% | ||
6 months | +67.79% | ||
Current year | +58.85% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 43.16 | +7.23% | 2,994 |
24-05-27 | 40.25 | -2.71% | 2,493 |
24-05-24 | 41.37 | -4.19% | 7,792 |
24-05-23 | 43.18 | +7.20% | 2,181 |
24-05-22 | 40.28 | +2.59% | 1,949 |
Delayed Quote London S.E., May 28, 2024 at 11:25 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- HNSA Stock
- 0RC7 Stock